BioSpace News Archive

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the hiring of industry veteran Girish Aakalu, Ph.D., as its new Chief Business Officer. I

Middlefield Group is pleased to announce that special meetings of unitholders of Middlefield Healthcare & Life Sciences Dividend Fund and REIT INDEXPLUS Income Fund were held today at which approximately 99.3% of the unitholders of Life Sciences and 96.7% of the unitholders of REIT present in person or represented by proxy voted in favour of respective resolutions authorizing the tax-deferred conversions of the Funds into exchange-traded funds, which are expected to occur in mid-February 2019.

Alternate Health Corp. announced today that the Company has closed a non-brokered private placement of 12,739,000 common shares at a price of CAD$0.40 per common share for aggregate gross proceeds of CAD$5,095,000.

Advancing medical device safety remains a top priority of the U.S. Food and Drug Administration. This means we are committed to communicating when new, relevant information becomes available about device safety risks, to ensure doctors and patients are better informed about device benefits and risks.

Astrotech Corporation announced the results of its fiscal year 2018 Annual Meeting of Shareholders held on December 7, 2018.

Assistance for UnitedHealthcare plan participants whose access to care or prescriptions needs may have been affected

Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced an underwritten public offering of 3,000,000 of its common shares.

Organogenesis Holdings Inc. today announced the completion of its previously announced business combination between Organogenesis Inc. and Avista Healthcare Public Acquisition Corp. (“AHPAC”).

Astellas Pharma Inc. today announced that XOSPATA® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.1

HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest.